Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 4948
Indexed In
- Index Copernicus
- Google Scholar
- CiteFactor
- Publons
- Pubmed
- science Gate
- scispace
- world cat
Useful Links
Related Subjects
Share This Page
Rediscovering clozapine
6th World Congress on Mental Health, Psychiatry and Wellbeing
Jason A. Gross
Pharmaceutical Executive, Canada
Posters & Accepted Abstracts: Int J Emerg Ment Health
Abstract
In 1989, clozapine was approved in the United States for Treatment-Resistant Schizophrenia (TRS), which after thirty years of use is still the only known treatment for TRS. In the United States, there are more than 3.5 million people living with schizophrenia, of which approximately 1 million have what is known as treatment-resistant schizophrenia. However, this treatment option is only offered to about 3% of eligible TRS patients are receiving treatment with clozapine. This lecture will explore the: (i) The perceived barriers to clozapine use (ii) Recent advances in clozapine care (iii) New technology for monitoring patients with TRS treated with clozapine (iv) Explore best practices for patients with TRS.Biography
E-mail: j.gross@hlstherapeutics.com
